Phase II/III Trial evaluating palovarotene in the patients with multiple osteochondromas (MO)
Phase of Trial: Phase II/III
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Palovarotene (Primary)
- Indications Bone cancer
- Focus Therapeutic Use
- Acronyms MO-Ped
- 20 Nov 2017 New trial record
- 13 Nov 2017 According to a Clementia Pharmaceuticals media release, Company has received regulatory feedback on the protocol for its Phase II/III MO-Ped study of palovarotene for the treatment of patients with MO, and expects to enroll the first patient in this global study by early 2018.
- 13 Nov 2017 According to a Clementia Pharmaceuticals media release, this trial expected to begin in early 2018.